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Renal involvement in von Hippel-Lindau disease. Renal involvement in
von Hippel-Lindau (VHL) disease has emerged as the most prevalent
cause of death in this hereditary disorder. in a group of 43 VHL patients
(23 unrelated families) with renal lesions we examined whether severity of
renal disease is affected by parental inheritance and VHL subtype (1,
without pheochromocytoma; 2, with pheochromocytoma). We also tested
whether and how nephron-sparing surgery could be applied. Renal
involvement comprised multiple cysts and bilateral and multifocal carci-
nomas (RCC) which were detected by screening in 38 patients, at 30.5 (14
to 62) years of age. The severity of the renal disease was similar in VHL
type 1 (79% of the pedigrees) and 2 (21%). It was not influenced by the
sex of the carrier. Twenty-nine patients were operated on at a mean age of
33.6 years: 21 patients (28 kidneys or 61% of all operated kidneys)
underwent nephron-sparing surgery, 4 had complete ablation of involved
kidneys and thus required dialysis, 3 had uninephrectomy and 1 had cyst
fenestration. Vascular thrombosis was the most severe early complication.
It occurred in 4 of 9 kidneys treated by ex vivo surgery. During a median
follow-up of 29 months, local recurrence occurred in 5 of 21 (24%)
patients treated by nephron-sparing surgery, whereas 2 developed metas-
tasis. Chronic renal failure (creatinine > 120 irmol/liter) affected 11
patients; in 9 of them, it was due to sequelae of surgery. In conclusion,
screening of RCC and nephron-sparing surgery are of value in VHL
patients. However, indications of ex vivo surgery should be drastically
restricted and renal sequelae are not uncommon. Renal followup is
required because of the risk of recurrence.
von Hippel-Lindau (VHL) disease is a dominantly inherited
disorder characterized by a predisposition to develop hemangio-
blastomas of the central nervous system and retina, pheochromo-
cytomas, pancreatic cysts and tumors and renal lesions [1—3]. The
unique gene responsible for VHL disease has been located and
identified on the short arm of chromosome 3 (3p2.5). In contrast
with genetic locus homogeneity, variable expression is customary
among families with the disease [4]. Some kindreds are prone to
pheochromocytomas (type 2 VHL disease), whereas they never
appear in others (type 1 VHL) [5, 6]. Within families, affected
members also exhibit phenotypic variability.
Kidney involvement ranges from simple cysts to renal tumors,
including atypical cysts with solid components. Multifocal lesions
are typical. Solid tumors are invariably renal cell (clear cell)
carcinomas (RCC) [710]. As most renal carcinomas develop at
an older age than any other complication, radiologic screening
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and early surgical treatment are advocated and presumably im-
prove long-term outcome. To delay end-stage renal failure in
otherwise severely affected VHL patients, nephron-sparing sur-
gery has been recommended [10—13].
The current study describes our experience with 43 VHL
patients having renal involvement. Our objectives were to delin-
eate the role of parental inheritance and VHL subtype on
phenotype variability and to test whether and how nephron-
sparing surgery could be applied to this group of patients.
Methods
Patient population
From 1986 to July 1995, 43 patients with VHL disease were
referred for renal involvement to our Clinic. Diagnosis of VHL
was established if the patient presented with one of the above-
mentioned lesions and a positive family history. In the absence of
family history (sporadic cases) lesions involving two different
systems were required [2]. Attention was devoted to renal involve-
ment in at-risk or affected relatives, including patient interview
and review of hospital and autopsy records.
Renal and extrarenal investigative workup
We currently screen for renal involvement by yearly abdominal
ultrasound from 15 years of age. If a renal lesion is detected, CT
scan of the abdomen is performed before and after contrast
media, using 5-mm-thick contiguous sections. Renal lesions are
classified as solid if their precontrast attenuation is greater than 20
UH and enhances with contrast material, or cystic if their
spontaneous attenuation is below 20 UH and does not enhance
after contrast media. High density lesions that do not enhance are
considered as cystic. Renal masses consisting of cysts with one or
few cloisons or a vegetant element, or both solid and cystic
components with a prominent cystic part, are classified as complex
lesions. Lesions are regarded as undetermined if their dimensions
are less than 5 mm. Magnetic resonance imaging (MRI) and renal
arteriography are applied in patients who are candidates for
renal-sparing surgery. MRI was performed preoperatively, using
body coil studying both kidneys in 10 patients, or dual surface coils
placed adjacent to the kidney being studied in 7 patients. In
addition, 6 kidneys requiring ex vivo surgery were studied by
intraoperative MRI.
Extrarenal assessment includes MRI of the brain and spinal
cord, blood pressure measurement, 24-hour urinary collection for
metanephrine and normetanephrine, and direct ophthalmoscopy.
In patients with solid renal lesions, chest X-ray is included.
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Fig. 1. Diagram showing the number and the
types of renal lesions identified by initial CT-scan,
the ages of patients at discovery, and the sex of
the carrier in VHL disease. The left side of the
Figure shows patients with "mild" and the right
side, patients with "severe" renal involvement.
The ordinate shows the number of renal
lesions, the abscissa, the ages at discovery.
Patients with both cystic and solid lesions were
Surgical management
It was considered in all patients presenting with at least one
solid or complex lesion greater than 25 mm. Nephron-sparing
surgery was regarded as the most appropriate approach if the
diameter of the renal lesion was less than 50 mm and if less than
5 to 6 solid lesions were identified pre-operatively in the ipsilateral
kidney. Solid lesions were excised by either partial nephrectomy
or wedge resection with a rim of normal surrounding renal tissue
or enucleation. We initially performed ex vivo tumor excision
using surface hypothermia and peroperative MRI screening for
detecting occult deep lesions and optimizing tumor withdrawal.
Autotransplantation was performed either at the original site (5
kidneys) or in the iliaca fossa (4 kidneys). Since 1994 all surgical
procedures have preferably been performed in situ. We have
never tried to remove purely cystic lesions. Synchronous resection
refers to bilateral surgical treatment within a six-month period,
even though bilateral renal-sparing operations were planned at an
interval of at least 30 days when indicated. Asynchronous resec-
tion refers to bilateral surgery distant by more than six months. If
warranted, radical nephrectomy (including adrenalectomy) was
performed. Bilateral radical nephrectomy was not performed in
patients with evidence of metastatic disease but no urologic
symptoms. Enlarged regional lymph nodes were biopsied at
operation. Postoperative followup of patients included physical
examination, chest radiography, abdominal CT and renal function
tests performed at six months and yearly thereafter.
Patholoi
For pathology study all surgical specimens were examined and
serially sliced. All lesions observed were prepared for routine light
microscopy analysis using hematoxylin-cosin, PAS and silver
methenamine staining. Simple cysts were defined as a single layer
of fiat chromophilic or clear cells lining the wall, atypical cysts as
a layer 2 or 3 clear cells thick, and cystic carcinomas as cystic
formations with at least one focus of multilayer clear cells or
papillary projections. All renal cell tumors were classified accord-
ing to Thoenes criteria, architectural growth and cytonuclear
atypias (Furhman's grade) [141.
For statistical analysis, we compared mean values with the
Mann-Whitney test. Statistical significance was taken at the 5%
level.
Results
Clinical presentation: Renal and extrarenal manifestations
We examined 43 patients (25 females, 18 males) with VHL
disease and kidney involvement. Renal lesions were detected
through presymptomatic screening in 38 patients, at initial eval-
uation in 17 patients, and during follow-up in 21. Age distribution
at diagnosis of renal involvement is depicted in Figure 1: mean
age was 30.5 years (range 14 to 62) for all patients and 30.6 (14 to
62) if only solid lesions are considered. Three patients had
widespread metastatic disease when diagnosis of RCC was first
considered at 31, 39 and 43 years of age, respectively. Renal
tumors were the only manifestation of von Hippel-Lindau disease
in two patients, at ages 22 and 62, respectively. Extrarenal
manifestations of von Hippel-Lindau disease are summarized in
Table 1. Mean age at diagnosis of first VHL manifestation was
28.0 years (range 9 to 62).
Family study: Parental inheritance and VHL subtype
A family history of VHL disease was traced in 37 out of 43
patients belonging to 23 apparently unrelated families. The dis-
ease was inherited from the father in 14 patients and from the
mother in 19. Inheritance remained unknown in 10 (including 6
sporadic cases). A total of 18 families (32 patients) and five
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Tabk 1. Extrarenal manifestations of von Hippel-Lindau disease in 43
patients with renal involvement
Lesion N %
Central nervous system
Retinal hemangioblastoma 22 51
Cerebral or brain-stem hemangioblastoma 28 65
Spinal cord hemangioblastoma 15 35
Abdominal lesions
Cystic pancreatic disease 26 60
Pancreatic solid tumors 4 9
Pheochromocytoma 5 12
Cystadenoma of broad ligament 1 2
Liver cysts 1 2
Giant liver hemangiomas 1 2
Others
Endolymphatic sac tumor 1 2
sporadic cases were classified VHL type 1 (79% of all pedigrees),
whereas five families (5 patients) and one sporadic cases were
VHL type 2 (21%). Mean ages at diagnosis of renal involvement
and first operation for RCC were not significantly affected neither
by parental inheritance nor by VHL subtype (1 or 2) (Table 2).
Clustering for severe renal involvement was observed in four
VHL type 1 families including 15 VHL members. In each of these
kindreds, two to four of the affected relatives (12 of 15) developed
metastasis or required bilateral renal surgery before 40 years of
age. So far we have not been able to characterize the molecular
lesions in these families.
Radiological findings
According to CT criteria, 823 lesions were initially character-
ized into four radiologically distinct patterns (Figs. 2 to 4 and
Table 3). Cysts were the most common lesions (34%) and were
found in 74% of the patients. Complex and solid patterns lesions
made up 35% of CT lesions. Solid lesions were observed in 34 of
43 patients, 19 having bilateral disease. Finally 31% of all lesions
remained too small (< 5 mm) during the study period to be
appropriately characterized. On follow-up, progressive enlarge-
ment of solid or complex renal lesions requiring surgery was
observed in 21 patients. Among eight patients initially exhibiting
renal cystic disease either isolated or associated with renal lesions
of unknown significance, only two developed solid lesions on
follow-up (mean 4.5 years).
Preoperative MRI was performed in 17 patients and findings
were concordant with CT in 8. MRI missed 37 lesions in 4
patients, 92% of them being less than 5 mm in size on CT-scan.
MRI helped to better characterize 15 lesions in 7 patients, only 3
being > 5 mm diameter. A selective renal angiogram was per-
formed in 24 patients and disclosed only 81 hypervascular tumors
in 34 kidneys (range 0 to 7 in each kidney), as compared to 139
solid tumors detected by CT. Angiography missed solid lesions
demonstrated by CT in 25 kidneys. Subsequently angiography was
proven to have missed one or more RCC in 24 out of 38 of the
operated kidneys.
Surgical procedures and follow-up
A total of 29 patients required surgical treatment (Table 4).
Three patients had previously undergone unilateral nephrectomy
before referral to this Renal Unit. First operation was performed
at a mean age of 33.6 10.9 years (range 18 to 59). Bilateral
Table 2. Natural history of renal lesions according to parental
inheritance and VHL phenotype
Inheritance VHL phenotype
Type I Type 2Paternal Maternal
(14 (19 (38 (5
patients) patients) patients) patients)
Age at diagnosis 30.5 3.0 28.5 1.5 31.6 1.8 38.4 5.4
N 14 19 38 5
Age if diagnosed by 30.0 3.4 28.0 1.6
screening
N 12 17
Age at 1st operation 35.4 2.8 29.8 3.1 31.8 2.1 42.7 5.8
N 12 10 25 4
Age at 1st operation 35.3 3.4 30.0 3.4
if diagnosed by
screening
N 10 9
Values are expressed as mean age (±SEM) in years
None of the above differences achieves statistical significance
disease (N = 18) required synchronous resection in 14 and
asynchronous surgery in 4 cases. Complete removal of involved
kidneys and renal replacement therapy was the only treatment
possible in four patients aged 25 to 43 years, having multiple renal
cell carcinomas (5 to 32 in each kidney) of moderate size (less
than 50 mm) but associated with numerous cysts precluding
sparing surgery. Eleven patients presented with unilateral disease
requiring surgery.
Our series comprises a total of 21 patients (28 kidneys) who
underwent nephron-sparing surgery. In addition, because of a
bilateral local recurrence, one patient underwent a repeat partial
nephrectomy in one kidney and nephrectomy in the other.
Therefore 29 nephron-sparing operations were performed on
these 21 patients, enabling in situ removal of 53 tumors from 19
kidneys and cx vivo resection of 31 tumors from 9 kidneys.
Intraoperative MRI detected 9 deeply seated lesions unidentified
on preoperative imaging, and reclassified three lesions as solid
tumors but missed two small RCC only discovered at examination
of one kidney. All but one of these tumors were less than 20 mm
in size.
No patient died in the perioperative period. Early complica-
tions included vascular thrombosis requiring kidney removal (N =
4), ischemic acute renal failure in patients with a solitary kidney(N = 3) without requirement for dialytic support, sepsis (N = 1)
and urinary fistula (N = 1). All occurred in patients treated by cx
vivo surgery. A single minor fistula occurred after in situ opera-
tion. Nephrectomies were uncomplicated. Regular dialysis was
started in four patients who became anephric, including one for
whom cx vivo operation failed.
On long-term follow-up (median 29 months, range 3 to 117)
chronic renal failure related to bilateral parenchymal removal
affected five additional patients (serum creatinine 120 to 172
lLmol/Iiter, stable over time). Progression of tumoral disease was
detected in 3 patients, either as local recurrence three years after
bilateral sparing surgery (N = 1) requiring reoperation of both
kidneys, or as distant metastasis (2 cases). In 4 additional patients,
recurrence of local tumoral disease was suspected on CT, the
lesions being still too small for firm identification. Extrarenal
manifestations related to VHL developed in 6 patients during the
follow-up period, including hemangioblastomas of the central
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Fig. 2. Patterns of renal lesions on CT-scan.
Numerous cysts with massively enlarged kidneys
mimicking autosomal dominant polycystic
kidney disease in a 36-year-old woman.
Fig. 3. Patterns of renal lesions on CT-scan.
Bilateral and multiple solid tumors in a 43-year-
old man with type 2 VHL disease.
nervous system (N =4), leading to death in one patient on regular requiring regular dialysis. Two nonoperated patients experienced
dialysis, hemangioblastoma of the retina (N = 1) and pancreatic extrarenal complications related to VHL disease.
solid tumor (N = 1).
Fifteen patients with renal involvement did not undergo sur- Patholo
gery, either because lesions were cystic or indeterminate but small
(N = 12), or disease was metastatic (N = 1) or renal replacement
therapy was declined (N = 2). On follow-up (mean 43 months, 9
to 144 months), 2 of them died of metastases, local progression of
renal solid tumors was demonstrated or suggested by CT in 4 and
2 patients, respectively, and regression of atypical cysts was
documented in 2. Two patients developed progressive renal
failure, attributed to invading cystic and tumoral disease (VHL
type 1, serum creatinine 222 .tmol/1iter), and to radiation nephri-
tis for malignant pheochromocytoma (VHL type 2), the latter
Three major types of gross lesions were recognized: solid
nodular lesions (0.2 to 6 cm in diameter), cystic lesions of variable
size (0.2 to 10 cm), most of them containing microscopic solid
formations; and white retracted scars at convexity in 6 kidneys.
A total of 219 RCC were removed from 46 kidneys. Detailed
study by light microscopy is available for 181 (Table 5). Twelve
percent included eosinophilic cell areas. Five kidneys included 10
to 32 carcinomas. Additionally 203 cysts were removed, and 138 of
them were examined histologically. The final diagnosis concluded
to (a) 16 (11%) cystic carcinomas, all clear cell type grade 1 with
Lesions'
r of patients with
Type
Number
(percent)
Numbe
Bilateral Unilateral No
Cysts 282 (34) 20 12 11
Complex 146 (18) 13 15 15
Solid 136 (17) 19 14 10
Undetermined 259 (31) 18 10 15
(size < 4 mm)
All 823 (100)
large cystic cavities, (b) 20 atypical cysts (14%), 0.3 to 7 cm, edged
with several layers of clear cells and (c) 102 simple cysts.
Widespread metastasis were present in one non-operated VHL
type I woman with several RCC in both kidneys, the largest being
45 mm in diameter. Conversely, large tumors (50 to 100 mm in
diameter) were removed in 5 VHL type 1 or 2 patients without
evidence of dissemination. Finally, a non-secreting pheochromo-
cytoma was incidentally found in 3 cases, whereas the adrenal
Solid tumors
(N = 195) %
Cystic lesions(N = 138) %
Renal cell carcinomas Simple cysts 75(N = 181)
Clear cell type 100
(N = 102)
Clear cells
Chromophilic cells
50
25
Chromophilic cells areas 12
Fuhrman grade
1 81
2 16 Atypical cysts 14
3 3 (N=20)
Architecture
Compact 50 Cystic carcinomas 11
Tubulocystic 50 (N = 16)
Tubular <1
Papillary 0
Fibrous nodules
(N = 14)
gland was enlarged in four additional cases (2 metastasis, 2
without evidence of tumor).
Discussion
Renal involvement is a frequent and commonly severe mani-
festation of von Hippel-Lindau (VHL) disease. Its incidence
reaches 24% in a retrospective review of the literature including
554 patients [2], 28% in a cohort of 152 patients followed in a
single center [3] and 31% in the French National VHL registry [9].
However, cumulative age distribution curves have shown that
among patients who survive to 60 to 70 years of age, 90 to 95%
develop kidney lesions [3, 15, 161. Of note, a longitudinal radio-
logical survey documented that at 60 years of age the cumulative
probability of diagnosis of renal cyst reached 95%, whereas solid
renal masses affected 77% of the population and platcaued
thereafter [81. In the last decade improvement in both screening
and treatment of hemangioblastoma and pheochromocytoma,
potentially fatal in young VEIL patients, has promoted RCC to the
leading cause of death [3, 15].
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Table 3. Radiological findings on initial CT-scan in 43 patients with
von Hippel-Lindau disease
Fig. 4. Patterns of renal lesions on CT-scan.
Cystic and complex lesions in a 23-year-old type
1 VHL patient.
Table 5. Histopathology of renal lesions in 46 kidneys from
29 VHL patients
a The absolute number of lesions do not include findings in two patients
(3 kidneys) with massively enlarged kidneys including unnumerable cysts
and solid lesions (Fig. 2)
Table 4. Surgical procedures performed in 29 VHL patients
Unilateral disease (N = 11)
Nephrectomy
Nephron sparing surgery (NSS)
Obstructive cyst fenestration
Bilateral disease (N = 18)
Bilateral nephrcctomy
Unilateral ncphrectomy and NSS
Bilateral NSS
3
7
4a
7h
a Including one patient with a single congenital kidneyb Including 3 patients who had undergone uninephrectomy prior to
referral to our hospital
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It should be stressed that the 43 patients included in our series
were referred to Necker Hospital for kidney involvement over a
ten year period. Concurrently extrarenal lesions were treated
elsewhere. Therefore our data do not provide insight into preva-
lence of renal lesions in VHL disease. However, renal involve-
ment was actually the initial manifestation in only 3 (7.2%)
patients in this series. Mean age at diagnosis of renal lesions,
either solid or not, was 30 years and 88% of them were detected
by screening. Such recruitement enables early diagnosis and most
likely explains discrepancies with the corresponding figures in the
series of Steinbach (36 years; 65 patients, 63% detected by
screening) and Maher (44 years; 43 patients, 18% detected by
screening) [3, 17]. Among the 34 patients with solid tumors, 19
(56%) had bilateral disease. An in depth review of the literature
by Nelson, Oyasu and Dalton also found that 56% of 138 VHL
patients with RCC had bilateral disease [12]. The updated expe-
rience from 8 medical centers in the United States, including 65
patients with presumably longer follow-up, suggests that this
number may even reach 83% [17].
The severity of the renal lesions is well exemplified in our series
where 29 of 43 (64%) patients required surgical treatment at a
mean age of 33.6 years, two to three decades prior to mean age at
surgery for sporadic RCC. Early discovery of RCC in VHL
disease has been stressed in the literature, with the diagnosis
being made at 15 [17] and at 16 years of age [18]. In addition,
bilateral renal surgery was required in 18 of 29 (62%) patients
who were operated on. Whether propensity to metastasize differs
in the sporadic and the VHL-related forms of RCC has been
questioned. In the sporadic form about half of the patients with
local recurrence after conservative surgery have concomitant
metastatic disease, at variance with the VHL form where the
corresponding number is 8% [171. Possibly smaller tumor size and
stage at initial removal partially explain these discrepancies.
Nevertheless, we documented metastasis in one patient whose
largest solid renal lesion did not exceed 45 mm.
What does promote the severity of the renal involvement?
Genetic factors are likely to play a role. In VHL type 2 families
with pheochromocytoma, two subtypes have been defined: 2A
without RCC, and 2B with RCC. In VHL 2A families a unique
505 T to C mutation has been detected [191, whereas in VHL 2B
families a hot-spot mutation was found at nucleotides 712 and 713
[20]. In contrast, no correlation has been found between genotypic
and renal phenotypic lesions in VHL type 1 families [6, 21], but
the risk of developing renal carcinoma is very high in these cases
(see above). Our data suggest a similar severity of kidney lesions
in VHL type I and 2B patients, albeit our series of type 2B
families is short. Interestingly, we showed that in 4 out of 18
(22%) VHL type 1 families, RCC exhibited a very aggressive
course. While genomic imprinting has been demonstrated to
influence the severity of some inherited disorders, the sex of the
carrier determining the profile of the disease in the offspring, this
possibility had not so far been explored in VHL disease. With
regard to RCC, we could not find evidence for genomic imprint-
ing.
In contrast, other VHL patients have a much less aggressive
renal disease. Some have only a single renal carcinoma, often
discovered late in life, simulating sporadic RCC. In the series
collected by Steinbach et al, 11 patients (17%) belonged to this
group [17]. In our group, four patients had a similar presentation,
including a 62-year-old man with an unilateral single RCC. The
rate of progression of RCC in VHL disease might be influenced
by the molecular mechanisms involved in carcinogenesis. The
VHL gene encodes a protein that binds to elongins B and C and
thus regulates the rate of transcription elongation mediated by
RNA polymerase H. Some mutations are located within the
elongin binding site of the VHL protein but some others are not
[22—25]. Inactivation of the VHL gene, a tumor suppressor gene,
may result from various mutations or from abnormal methylation
[26, 27]. It is also suggested that other as yet unidentified factors
possibly protect against multicentric or aggressive RCC in some
patients or families.
In addition, VHL renal involvement may present as only cysts.
Eight of our patients had purely cystic disease. This peculiar
phenotype may also arise after 60 years of age [28]. Pathogenesis,
prognosis and treatment of renal cysts raise unsolved issues. The
renal cyst epithelium is often atypical in VHL, with multiple cell
layers and foci of cells highly suggestive of RCC in 25% of our
specimens as in previous studies [7, 10]. Studies by antigenic
markers indicate some similarity between cyst epithelial cells and
renal carcinoma cells [29]. However, long-term follow-up by
CT-scan of 168 cysts in 28 patients over a five-year period
documented only two transformations into solid tumors, whereas
7% of the cysts spontaneously involuted [8]. Despite these results,
these authors advocated later extensive excision of all visible cystic
lesions when concomitant solid tumours require surgery [281. We
have elected a much more conservative approach.
Surgical management of renal lesions in VHL disease requires
an individualized approach. This includes careful evaluation of
both central nervous system lesions, whose surgical care may be
indicated and then has priority, and functional pheochromocy-
toma, which should be excised prior to or at the same time as renal
surgery [30J. Surgical options for solid renal tumors of significant
size (> 25 mm) are nephrectomy, which exposes to renal failure in
case of bilateral disease, and nephron-sparing surgery which
carries the risks of residual disease or local recurrence in the
remnant renal parenchyma and subsequent metastasis [11, 31].
Like others, we opted for sparing surgery when possible and
treated accordingly 28 kidneys from 21 patients (61% of all
operated kidneys). We agree with the conclusion meanwhile
reached by Walther et al that "in VHL patients, solid renal lesions
should be removed when they are  30 mm in diameter," and that
"smaller neoplasms centrally located or adjacent to vital struc-
tures may also be indications for earlier renal operations." We
documented local recurrence in 5 of 21 patients (24%) at 31
months, in keeping with the 36% rate found at 26 months among
19 patients [28]. Both experiences are too short at the moment to
confirm that this attitude is well-founded on the long term. The
multicenter experience collected by Steinbach in 49 patients in the
meantime provides a rationale to support this approach since 5-
and 10-year cancer specific survival rates were evaluated at 100
and 81 %, respectively. Simultaneously, the corresponding rates of
local recurrence were 29 and 85% [171. Only 2 of 49 patients (4%)
developed metastasis in the series mentioned above, but 2 of 21
(9%) in our experience. Close follow-up and repeat surgery are
thus the counterpart of nephron sparing surgery.
Intraoperative detection of small lesions may be of value to
increase the efficacy of nephron-sparing surgery. Compared with
preoperative imaging, we documented that intraoperative MRI
enhances both sensitivity and specificity to characterize the small
(< 10 mm) renal lesions in VHL disease. Despite caution in
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cooling the kidney transiently removed, intraoperative MRI pro-
longed ischemia time and might have contributed to the high rate
of vascular thrombosis we observed. The reliability of intraoper-
ative ultrasound for localization of small lesions is also debated:
some had little success in finding nonpalpable solid tumors [311,
whereas others concluded that 38% of resected lesions had not
been detected on preoperative imaging [32]. Despite this in-
creased excision of small tumors, recurrence reached 36% at two
years in this series [28].
Conservative surgery not being possible or not considered, a
total of 17 kidneys were initially removed in our patients. Presum-
ably long-term survival should be less in these patients, most of
whom had a more aggressive renal disease than in the nephron-
sparing group. Five- and 10-year survival rates were 95 and 77%
in 16 patients reviewed in the multicenter study [17].
Chronic renal failure affected 11 of our 43 patients (26%). Of
note, one patient developed severe renal failure in association
with diffuse bilateral cystic and solid tumors. Hauschild also
reported a 51-year-old man requiring regular hemodialysis for
VHL disease mimicking autosomal dominant polycystic kidney
disease who died four months later of widespread metastases of
RCC [33]. The mechanism of reduced glomerular filtration rate in
our case may be related to cystic compression of renal paren-
chyma or alternatively to its infiltration by cancer. End-stage renal
disease has so far not been reported in the purely cystic form of
VHL disease. Sequelae of renal surgery accounted for renal
failure in 9 of 11 patients, including four requiring regular dialysis.
Steinbach et al recently reported that despite attempted nephron-
sparing surgery, 15 of 65 patients (23%) ultimately developed
end-stage renal failure [17]. The most serious complication of
renal surgery was postoperative vascular thrombosis, which oc-
curred in 4 out of 9 & vivo operations. Owing to these pitfalls we
have drastically restricted the indications of & vivo surgery, which
together with extensive parenchymal resection are now well
identified risk factors for severe complication of sparing surgery
[34, 35]. For patients on renal replacement therapy without
metastatic malignancy, renal transplantation is advisable if extra-
renal features do not preclude it. At least 19 VHL patients have
received this form of replacement therapy [17, 36, 37]. The
optimal interval (1 or 2 years) between kidney removal and
transplantation in order not to miss residual malignancy, as well as
long term survival, are not known.
Reprint requests to Dr. D. Chauveau, Department of Nephrology, ffôpital
Necker, 161, rue de Sèvres, 75015 Paris, France.
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